Previous 10 | Next 10 |
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today received notice regarding the U.S. Patent Office (USPTO) Patent Trial and Appeal Board (PTAB) decision to institute trial on the Inter Partes review (“IPR”) filed...
Potential M&A interest in Aurinia Pharmaceuticals ( NASDAQ: AUPH ) could be hampered -- at least in the short-term -- by a board's review of a patent related to the company's lupus drug Lupkynis (voclosporin), according to Cantor Fitzgerald. Shares are down 7% in l...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for the second quarter of 2022 on Thursday, August 4, 2022, before markets open. Aurinia’s management team w...
Hanger ( HNGR ) +25% on deal to be taken private at $1.25B enterprise value. Stronghold Digital Mining ( SDIG ) +21% . Yoshitsu ( TKLF ) +20% enters into definitive agreement to acquire Tokyo Lifestyle Limited. Applied Blockchain ( APLD ...
Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH ) announced on Friday that an advisory committee of the European Medicines Agency (EMA) issued a positive opinion on its lupus nephritis drug Lupkynis recommending its marketing authorization in the region. The decisi...
Positive CHMP opinion is based on a comprehensive submission including data from the pivotal AURORA 1 efficacy study and the AURORA 2 continuation study, demonstrating voclosporin to be safe and well tolerated for up to three years of treatment. Based on the CHMP recommendatio...
Our next Marketplace Contributor Roundtable Series will be a Q2 Earnings Preview. To kick off, we have responses from 16 Marketplace contributors on Tech and Growth stocks. The series continues next week with everything from Dividends to Value Stocks and Macro coverage. As alw...
Gainers: Vertical Aerospace ( EVTL ) +31% . NexImmune ( NEXI ) +31% . 180 Life Sciences ( ATNF ) +21% . ToughBuilt Industries ( TBLT ) +20% . Energy Vault Holdings ( NRGV ) +17% . EyePoint Pharmaceuticals ( EYPT ) +...
Shares of small-cap autoimmune disease specialist Aurinia Pharmaceuticals (NASDAQ: AUPH) were down by a hefty 13.5% as of 10:50 a.m. ET Friday morning. This double-digit move southward was also accompanied by a healthy surge in the stock's daily volume. What's sparking this sudd...
Aurinia Pharmaceuticals ( NASDAQ: AUPH ) plunged 14% after the company announced Thursday three new executive hires, including a new R&D chief, likely cooling speculation that the company may be acquired. Aurinia also disclosed that its chief commercial officer will be...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...